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See Article, pages 677–685Over the last decade immunotherapy has progressively gained a
signiﬁcant clinical interest for cancer treatment.
The actual beneﬁt of active immunotherapy, namely cancer
vaccines, has been repeatedly claimed as effective in several set-
tings and prompted prospective investigations (phase III clinical
trials) currently ongoing in patients with prostate carcinoma,
melanoma, and lung cancer, while the ﬁrst vaccine for the treat-
ment of metastatic prostate carcinoma has been recently
approved by the FDA [1,2].
Adoptive immunotherapy, based on the administration of anti-
bodies (Ab) targeting tumor receptors or molecules expressed in
the microenvironment, has also entered clinical practice in sev-
eral cancers such as breast carcinoma, colorectal cancer, and hae-
matological tumors [3], whereas adoptive transfer of ex vivo
activated tumor-speciﬁc T cells has shown dramatic efﬁcacy in
metastatic melanoma [4], a known benchmark-tumor for
immune manipulations both in animal and human models.
Ab-therapy of cancer was initially conceived to directly elim-
inate tumor cells by interfering with the activity of either recep-
tors involved in cancer cell proliferation (e.g. members of the HER
family) or molecules regulating tumor blood supply (such in the
case of anti-VEGF Ab) [5]. However, the clinical efﬁcacy of
broadly used Ab was subsequently found to rely, at least in part,
on the contribution of the immune system through the activation
of antibody-dependent cell cytotoxicity (ADCC) mediated by cel-
lular components of innate immunity [5,6]. NK cells, monocytes,
macrophages, and granulocytes can indeed bind to Ab thanks to
the expression of speciﬁc receptors for the invariant portion of
this molecule (the so called Fc portion) and be recruited to attack
target cells, hence contributing to the therapeutic potential of Ab-
based therapies. Evidence proving such mechanism has been col-
lected in preclinical studies, showing that anti-tumor antibodies,
like trastuzumab, have reduced activity when administered in
FcR knock-out mice or used in a FcR-binding defective form.
Similarly in clinical setting, breast cancer trials have reported
immune inﬁltrate in cancer lesions of Ab-treated patients, and
better efﬁcacy in subjects expressing deﬁned FcR genotypes [6].
More recently, the anti-tumor activity of such strategy has been
also potentiated through bi-speciﬁc engineered single-chain Ab
designed to tether cytotoxic T lymphocytes to cancer cells, anJournal of Hepatology 20
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pen access under CC BY-NC-ND license.approach associated with signiﬁcant responses in patients with
non-Hodgkin’s lymphoma [7].
Most human cancers are currently acknowledged to be the tar-
get of some type of immune recognition; among them colorectal
carcinoma (CRC) has been unequivocally proven to be under the
control of tumor immunity, particularly in the early phases of its
development. Indeed the presence of T cells with memory pheno-
type inﬁltrating primary tumor lesions showed a favourable prog-
nostic impact in patients with CRC, suggesting how host immune
surveillance may initially impact the course of the disease [8].
However, with cancer progression, immunological defects target-
ing both innate and adaptive immunity tend to accumulate,
blunting initial defences for promoting an immunosuppressive
pro-tumorigenic environment [9,10]. In fact, as a consequence of
intrinsic tumor pathways or chronic inﬂammation, dendritic cells
and macrophage with altered stimulating activity, together with
regulatory T cells and myeloid-derived suppressor cells, expand
in vivo and exert potent inhibitory effects on anti-tumor immunity
[10].
Because of this, any form of immunotherapy relying on the
contribution of the host immune system ﬁnds its ideal applica-
tion in early disease or in the adjuvant setting, when the tumor
burden is still microscopic and the host’s immune function is
mostly preserved.
Adjuvant immunotherapy to prevent hepatic metastases from
CRC is actually the setting chosen by van der Bij and collabora-
tors, [11] who report, in the present issue, the successful use of
a speciﬁc anti-tumor Ab to inhibit, in a rat model, the growth
of metastatic CRC cells injected into the liver through the portal
system. This experimental setting has some limitations with
respect to real patients in which CRC cells spill into the portal
system from a primary intestinal tumor site that owns variable
predisposition to venous invasion. However, in the absence of
the primary tumor component, this study is actually reminiscent
of two crucial conditions that may affect the outcome of patients
with CRC: (1) the fact that microscopic tumor cell deposits in the
liver precede the development of an unknown proportion of such
cells into clinically established metastases, and (2) the potential
pro-tumorigenic effect of surgical intervention, possibly related
to the production by healing tissues of growth factors, angiogen-
esis mediators, inﬂammatory cytokines, and chemokines [12,13],
with consequent advocacy of minimally invasive techniques in
removing primary colorectal cancer sites.10 vol. 53 j 596–598
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The study of van der Bij et al. depicts the possibility of pre-
venting liver metastases by post-operative (adjuvant) adminis-
tration of a tumor-speciﬁc monoclonal Ab, whose potent
prophylactic effect was not directly mediated by the Ab itself
but required the activation of local immune effectors, namely
Kupffer cells (KC) and possibly monocytes.
One of the innovative aspects of the present work is indeed
the idea of speciﬁcally exploiting resident components of the
innate immunity to promote cancer cell clearance in the liver.
Indeed, immunologists consider the liver a lymphoid organ
[14] hosting a wide variety of immune cells, particularly KC
which are liver-conﬁned macrophages with prompt phagocytic
and cytotoxic activity [15]. KC are acknowledged to provide a
second line of defense in mucosal immunity by eliminating
invasive microorganisms entering through the portal circulation
and thus preventing disease thanks to their expression of differ-
ent immune receptors (such as for instance FcR) [16]. It is hence
conceivable that they may also act as a sentinel in eliminating
tumor cells if appropriately stimulated, as clearly suggested by
van der Bij and collaborators. Although the expression of
immune-related receptors surely differs in rodents and humans
[17], KC may undoubtedly represent a useful ally for reducing
the incidence of liver metastases in CRC patients, pending the
identiﬁcation of the optimal stimuli for rescuing their anti-
tumor activity.
Interestingly, the liver is also rich in resident NK cells [14], the
immune subset mostly involved in ADCC in humans. Tumor-spe-
ciﬁc Ab capable of engaging both KC and NK cells by binding to
common receptors and possibly promoting a positive cross-talk
(such as toll-like receptor agonists [18]) should help maximizing
the local effect on tumor control.
Additional key points to be addressed in case of clinical appli-
cations of the proposed strategy are: the choice of antibodies able
to bind efﬁciently and speciﬁcally to CRC cells rather than normal
cells; the identiﬁcation of tumor antigens possibly playing a role
in regulating tumor cell proliferation, to be targeted by these Ab,
and the homing capacity of the chosen Ab that could be potenti-
ated, as in the described study, by intra-portal surgical routing.
Besides the family of epidermal growth factor receptors, other
appealing antigens to be targeted are represented by mucins,
broadly expressed [19], and already tested as target of spontane-
ously or vaccine-induced immune responses in CRC patients [3].
Also the newly identiﬁed CP1 (cancer placenta 1) is highly
expressed in CRC cells and is able to elicit both humoral and cel-
lular immune responses correlated with survival in CRC patients
[20].
If the innate liver immunity could be triggered by Ab to con-
trol growth of metastatic tumor deposits into the liver, activation
of adaptive immunity through the administration of a cancer vac-
cine could provide the additional advantage of inducing a protec-
tive immunological memory for long-term and systemic disease
control, a feature that would not be directly induced by Ab-ther-
apy. Indeed, we have shown that an anti-tumor vaccine
(composed by heat shock protein 96 extracted from liver metas-
tases) can signiﬁcantly reduced the recurrence rate and prolong
survival in CRC patients mounting a CD8-mediated tumor-spe-
ciﬁc response to immunization [21,22]. Cancer vaccines could
hence be administered in combination with Ab for more full-
ﬂedged immune mediated tumor control. With liver being an
organ where potent CD8+ T cell priming can occur, cancerJournal of Hepatology 201vaccines could also be administered locally to promote activation
of resident tumor-speciﬁc T cells [14].
More extensive studies on the role of resident liver immunity
in controlling local tumor growth should thus be encouraged,
together with a ﬁne analysis of the immunological features of
resident KC, macrophages, and NK cells in the liver. Most impor-
tantly, translation of the achieved results into the clinical setting
should be accelerated, to test whether adjuvant immunotherapy,
possibly combining tumor-speciﬁc Ab and vaccines, can signiﬁ-
cantly impact the course of disease in CRC patients.Conﬂict of Interest
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